<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=undefined&type=result"></script>');
-->
</script>

COPY SCRIPT

For further information contact us at helpdesk@openaire.eu

Structure activity relationship studies of natural product chemokine receptor CCR5 antagonist anibamine toward the development of novel anti prostate cancer agents

descriptionPublicationkeyboard_double_arrow_right Article , Other literature type 01 Sep 2012Publisher:Elsevier BVJournal:European Journal of Medicinal Chemistry, volume 55, pages 395-408 (issn: 0223-5234,

Authors: Harrison C. Fang; Amanda C. Richardson; John E. Bajacan; Feng Zhang; Yan Zhang; Christopher K. Arnatt; Kendra M. Haney; +1 Authors

doi: 10.1016/j.ejmech.2012.07.049 , 10.1002/chin.201304150

pmid: 22901310

Structure activity relationship studies of natural product chemokine receptor CCR5 antagonist anibamine toward the development of novel anti prostate cancer agents

- Summary
- Subjects
- Related research
  (10)
- Metrics

Abstract

AbstractDesign, syntheses, and anti prostate cancer activities of new anibamine analogues (I) and (II) are described.

Related Organizations

Virginia Commonwealth University
United States
VCU Massey Comprehensive Cancer Center
United States

Keywords

Male, Biological Products, Pyridines, Prostatic Neoplasms, Antineoplastic Agents, Xenograft Model Antitumor Assays, Mice, Structure-Activity Relationship, Cell Line, Tumor, CCR5 Receptor Antagonists, Drug Discovery, NIH 3T3 Cells, Animals, Humans, Calcium, Chemokine CCL5, Cell Proliferation

Filter by relation

All relations

arrow_drop_down

10 Research products, page 1 of 1

Anibamine and Its Analogues: Potent Antiplasmodial Agents from Aniba citrifolia
2019IsAmongTopNSimilarDocuments
Anibamine and its Analogues as Novel Anti-Prostate Cancer Agents
2009IsAmongTopNSimilarDocuments
The potential role of anibamine, a natural product CCR5 antagonist, and its analogues as leads toward development of anti-ovarian cancer agents
2012IsAmongTopNSimilarDocuments
BindingDB Entry 50033779: The natural product CCR5 antagonist anibamine and its analogs as anti-prostate cancer agents.
2012IsAmongTopNSimilarDocuments
Comparative Docking Study of Anibamine as the First Natural Product CCR5 Antagonist in CCR5 Homology Models
2009IsAmongTopNSimilarDocuments
BindingDB Entry 50046399: Exploration on natural product anibamine side chain modification toward development of novel CCR5 antagonists and potential anti-prostate cancer agents.
2016IsAmongTopNSimilarDocuments
Isolation and Structure of Antagonists of Chemokine Receptor (CCR5)
2004IsAmongTopNSimilarDocuments
BindingDB Entry 50040131: Structure activity relationship studies of natural product chemokine receptor CCR5 antagonist anibamine toward the development of novel anti prostate cancer agents.
2013IsSourceOf
BindingDB Entry 50040131: Structure activity relationship studies of natural product chemokine receptor CCR5 antagonist anibamine toward the development of novel anti prostate cancer agents.
2013IsAmongTopNSimilarDocuments
BindingDB Entry 50040016: The potential role of anibamine, a natural product CCR5 antagonist, and its analogues as leads toward development of anti-ovarian cancer agents.
2013IsAmongTopNSimilarDocuments

Impact byBIP!

	citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	17
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Top 10%
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Top 10%